Deal Details

Valuence Completes $220 Million IPO

Healthcare

Valuence IPO

Summary

Valuence Merger Corp. I ("Valuence or the "Company") recently completed an initial public offering of 22,099,630 units at a price of $10.00 per unit, generating gross proceeds of $220 million. Each unit consists of one class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder to purchase one class A ordinary share at a price of $11.50 per share. The Company intends to use the net proceeds from this offering to effect a future business combination.

Baird served as lead manager on this offering.

About

Valuence is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an acquisition in any business or industry, it intends to focus its search on businesses in Asia (excluding China, Hong Kong and Macau) with a focus on breakthrough technology in life sciences and/or sustainable technology. The management team is led by Sung Yoon Woo, Andrew Hyung, Sung Lee and Gene Cho. The Company expects to collaborate with CrystalBioSciences, a venture capital firm focused on life sciences, Credian Partners, a South Korea-based private equity firm, and Quantum Leaps, a Japan-based consulting firm that was founded by Mr. Nobuyuki Idei, a former Chairman, CEO and President of Sony. Valuence Merger Corp. I is headquartered in Orinda, California.

Healthcare

Valuence IPO